Home | Welcome to Contract Pharma   
Last Updated Friday, September 19 2014
Print RSS Feed

Financial Report: PDL BioPharma



Published May 10, 2013
PDL BioPharma

1Q Revenues: $91.8 million (+19%)

1Q Earnings: $53.5 million (+33%)

Comments: Royalty revenues were up 19% driven by increased royalties from Avastin, Herceptin, Lucentis, Tysabri, and Actemra.


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On